Abstract

Accomplishments: 1. Higher than expected accrual to the phase III clinical trial, NSABP B38 with projected complete in 4/2007.2. NSABP B30 had another interim analysis but the results have not been made public at this time. 3. Adjuvant trastuzumab (Herceptin) results were published in the NEJM which conclude that the disease-free survival was increased by an absolute number of 18% in patients who received trastuzumab. This is a truly remarkable benefit utilizing a biologic therapy. It indicates that if the correct target is identified that is responsible for carcinogenesis and this is based on biology that major advances can be made.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010560-03
Application #
7338644
Study Section
(MOB)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2006
Total Cost
Indirect Cost

  Institution

Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Korde, Larissa A; Lusa, Lara; McShane, Lisa et al. (2010) Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 119:685-99
Yang, Sherry X; Steinberg, Seth M; Nguyen, Dat et al. (2008) Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 14:5893-9
Dennison, Sheri K; Jacobs, Samuel A; Wilson, John W et al. (2007) A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs 25:545-51
Yang, Sherry X; Hewitt, Stephen M; Steinberg, Seth M et al. (2007) Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 17:281-7
Denduluri, Neelima; Low, Jennifer A; Lee, James J et al. (2007) Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25:3421-7
Walshe, Janice M; Berman, Arlene W; Vatas, Ujala et al. (2007) A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat 103:177-83
Portera, Chia C; Swain, Sandra M (2007) The heart of the matter. J Clin Oncol 25:3794-6
Thukral, Arpi; Thomasson, David M; Chow, Catherine K et al. (2007) Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. Radiology 244:727-35
Denduluri, Neelima; Lee, James J; Walshe, Janice et al. (2007) Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 25:63-7
Orzano, Jennifer A; Swain, Sandra M (2005) Concepts and clinical trials of dose-dense chemotherapy for breast cancer . Clin Breast Cancer 6:402-11

Showing the most recent 10 out of 14 publications